Management of Atrial Fibrillation with Moderate Ventricular Response

Initial Rate Control Strategy

The American College of Cardiology recommends beta-blockers, non-dihydropyridine calcium channel blockers, or digoxin for initial rate control in atrial fibrillation with moderate ventricular response, with the choice depending on the patient's cardiac function and comorbidities 1, 2
Beta-blockers or non-dihydropyridine calcium channel antagonists are first-line medications for rate control in patients with preserved left ventricular ejection fraction (LVEF >40%) 1, 3
For patients with heart failure with reduced ejection fraction (LVEF ≤40%), beta-blockers and/or digoxin are recommended as first-line agents 1, 2
A lenient heart rate target of <110 beats per minute at rest is an appropriate initial goal for most patients 3
Intravenous administration of beta-blockers or calcium channel antagonists is recommended in the acute setting to rapidly control ventricular response, with caution in patients with hypotension or heart failure 1

For patients with preserved LVEF (>40%), beta-blockers are preferred in patients with coronary artery disease, myocardial ischemia, or hyperthyroidism 1
Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are preferred in patients with bronchospastic lung disease 1
For patients with reduced LVEF (≤40%) or heart failure, intravenous digoxin or amiodarone is recommended for acute rate control 1
Beta-blockers should be used cautiously in patients with decompensated heart failure 1

A combination of digoxin and a beta-blocker (or a non-dihydropyridine calcium channel antagonist for patients with preserved LVEF) is reasonable when monotherapy is insufficient for rate control 1
Oral amiodarone may be considered when heart rate cannot be adequately controlled using other agents alone or in combination 1

For patients who remain symptomatic despite adequate rate control, a rhythm control strategy may be considered 5, 3
AV node ablation with ventricular pacing is reasonable when pharmacological therapy is insufficient or not tolerated 1
For patients with AF and tachycardia-induced cardiomyopathy, either aggressive rate control or rhythm control is recommended 1

Anticoagulation therapy should be administered based on stroke risk assessment using the CHA₂DS₂-VASc score, regardless of the rate control strategy 3
Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists for eligible patients 3